Oxford Nanopore Technologies raises £195m in Series H+ investment from new and existing backers
M&G Investments contributed £35m to the £195m private transaction alongside Temasek, Wellington Management, and Nikon.
Oxford Nanopore Technologies develops DNA and RNA sequencing solutions used across scientific research and public health applications. Founded in 2005 as a spin-out from the University of Oxford, the business provides technology to characterise pathogens and advance biomedical science.
Oxford Nanopore Technologies has secured £195m in a Series H+ private transaction. The capital injection comprises £125m from new investors including Temasek, Wellington Management, M&G Investments, and Nikon, alongside £70m from existing shareholders.
The funding adds to the company's financial backing as it continues its previously announced strategic plans. M&G Investments contributed £35m of the total through its Catalyst team, which targets privately owned enterprises addressing sustainability.
Institutional participation in the round highlights the role of long-term savings funds in supporting enterprises with broader societal benefits. The company operates from Oxford, providing sequencing technology used globally in biomedical research and public health.
Investor perspective
"The technology developed by Oxford Nanopore is being used in a broad range of scientific research applications, including to further biomedical science, to characterise pathogens in microbiology and public health. This is an example of how institutional investors can play an important role in accelerating growth in companies that provide a wider benefit to society."
Jack Daniels
Chief Investment Officer, M&G Investments
Investors
Categories
About the company
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops DNA and RNA sequencing systems for scientific research and public health.